136
Views
9
CrossRef citations to date
0
Altmetric
Letter to the Editors

High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma

, , , , , , , & show all
Pages 1363-1366 | Received 22 Sep 2010, Accepted 10 Mar 2011, Published online: 25 May 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Theodoros Karantanos, Ioannis Politikos & Vassiliki A Boussiotis. (2017) Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies. Blood and Lymphatic Cancer: Targets and Therapy 7, pages 37-52.
Read now
Ioanna Sakellari, Despoina Mallouri, Ioannis Batsis, Chrysa Apostolou, Varnavas Konstantinou, Eleni-Maria Abela, Vasiliki Douka, Anastasia Marvaki, Kyriakos Karypidis, Michalis Iskas, Panayiotis Baliakas, Panayotis Kaloyannidis, Evangelia Yannaki, Damianos Sotiropoulos, Giorgos Kouvatseas, Christos Smias & Achilles Anagnostopoulos. (2015) Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas. Leukemia & Lymphoma 56:11, pages 3071-3081.
Read now

Articles from other publishers (7)

Xiao-Yu Chen, Xiao-Hua Qin, Xiao-Ling Xie, Cai-Xiang Liao, Dong-Ting Liu & Guo-Wei Li. (2022) Overexpression miR-520a-3p inhibits acute myeloid leukemia progression via targeting MUC1. Translational Oncology 22, pages 101432.
Crossref
Gregorio Jaimovich, Maria Belen Rosales Ostriz, Martin Castro, Leandro Riera, Cecilia Foncuberta, Hector Longoni, Agustina Cia, Patricio Duarte, Adriana Vitriu, Francisco Lastiri & Robert Peter Gale. (2019) CBeV (cyclophosphamide, bendamustine and etoposide) pre-autotransplant conditioning in persons with lymphoma. Bone Marrow Transplantation 55:1, pages 265-267.
Crossref
Paolo Bernasconi & Oscar Borsani. (2019) Targeting Leukemia Stem Cell-Niche Dynamics: A New Challenge in AML Treatment. Journal of Oncology 2019, pages 1-12.
Crossref
Christopher R. Flowers, Luciano J. Costa, Marcelo C. Pasquini, Jennifer Le-Rademacher, Michael Lill, Tsiporah B. Shore, William Vaughan, Michael Craig, Cesar O. Freytes, Thomas C. Shea, Mitchell E. Horwitz, Joseph W. Fay, Shin Mineishi, Damiano Rondelli, James Mason, Ira Braunschweig, Weiyun Ai, Rosa F. Yeh, Tulio E. Rodriguez, Ian Flinn, Terrance Comeau, Andrew M. Yeager, Michael A. Pulsipher, Isabelle Bence-Bruckler, Pierre Laneuville, Philip Bierman, Andy I. Chen, Kazunobu Kato, Yanlin Wang, Cong Xu, Angela J. Smith & Edmund K. Waller. (2016) Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Biology of Blood and Marrow Transplantation 22:7, pages 1197-1205.
Crossref
Nishitha M. Reddy & Miguel-Angel Perales. (2014) Stem Cell Transplantation in Hodgkin Lymphoma. Hematology/Oncology Clinics of North America 28:6, pages 1097-1112.
Crossref
Mark Hertzberg. (2014) Relapsed/Refractory Hodgkin Lymphoma. Hematology/Oncology Clinics of North America 28:1, pages 123-147.
Crossref
Anna ColpoEphraim Hochberg & Yi‐Bin Chen. (2011) Current Status of Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma. The Oncologist 17:1, pages 80-90.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.